FindMyKOL
Clinical trialNCT03822325Active, not recruitingObservational

Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis

NCT03822325 is an observational study sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. As of 21 Nov 2026, it is active and no longer recruiting. It studies Eosinophilic Esophagitis. The registry lists an enrollment of 88 participants at 2 sites in 1 country. The registry lists a start date of 28 Feb 2011 and a primary completion date of 31 May 2015.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03822325
FieldValue
Registry IDNCT03822325
StatusActive not recruiting
Study typeObservational study
Lead sponsorAnn & Robert H Lurie Children's Hospital of Chicago
Enrollment88
Registered sites2
Countries1
ConditionsEosinophilic Esophagitis
Start28 Feb 2011
Primary completion31 May 2015
Study completion30 Nov 2027
Last update posted5 Jun 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The investigators seek to assess esophageal inflammation or lack of it in response to treatment with a novel non-invasive method that would measure eosinophil-associated inflammatory mediators in the blood and urine to determine the presence of active Eosinophilic Esophagitis. For these purposes, the investigators will correlate esophageal inflammatory mediators measured in blood and urine with histological findings identified on esophageal mucosal biopsies. Additionally, biopsies associated mediators will be assessed relative to clinical phenotype and outcome.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Barry Wershil, MD

    Ann & Robert H. Lurie Children's Hospital fo Chicago

    Principal Investigator
  • Joshua Wechsler, MD

    Ann & Robert H Lurie Children's Hospital of Chicago

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Illinois, United States2 sites
  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago

  • University of Illinois at Chicago (uic)

    Chicago

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 2 sitesIL2IndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT03822325

Each answer restates registry values shown on this page.

What is NCT03822325?

NCT03822325 is an observational study sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. It studies Eosinophilic Esophagitis.

Is NCT03822325 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT03822325?

The registry names Barry Wershil, MD (principal investigator, Ann & Robert H. Lurie Children's Hospital fo Chicago) and Joshua Wechsler, MD (principal investigator, Ann & Robert H Lurie Children's Hospital of Chicago) as overall officials.

Where does NCT03822325 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

When is NCT03822325 expected to complete?

The registry lists a primary completion date of 31 May 2015 and a study completion date of 30 Nov 2027. The sponsor last updated the record on 5 Jun 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.